Inactive Instrument

News Vivoryon Therapeutics AG Euronext Amsterdam

Equities

DE0007921835

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024	Apr. 16	GL
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Announces Changes to Board Composition	Mar. 15	PU
Vivoryon Therapeutics N.V. Announces Changes to Board Composition	Mar. 15	GL
Vivoryon Therapeutics N.V. Announces Changes to Board Composition	Mar. 15	AQ
Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	Mar. 15	CI
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease	Mar. 04	PU
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease	Mar. 04	GL
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease	Mar. 04	AQ
Vivoryon Therapeutics N.V. Provides Update on Viviad Phase 2B Study of Varoglutamstat in Early Alzheimer?S Disease	Mar. 04	CI
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024	Jan. 08	GL
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024	Jan. 08	AQ
Transcript : Vivoryon Therapeutics N.V., Q3 2023 Earnings Call, Dec 06, 2023	Dec. 06
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress	Dec. 06	GL
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress	Dec. 06	AQ
Vivoryon Therapeutics N.V. Announces Executive Changes	Dec. 06	CI
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023	Nov. 28	GL
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference	Nov. 07	GL
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision	23-10-26	GL
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision	23-10-26	AQ
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision	23-10-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Vivoryon Therapeutics AG Euronext Amsterdam

Equities

DE0007921835

Summary

Filters